|
US1548716A
(en)
|
1924-10-02 |
1925-08-04 |
Fournier Santiago Emilien |
Process for the manufacture of artificial freestone
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
AU663725B2
(en)
|
1991-08-20 |
1995-10-19 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
ES2249761T3
(es)
|
1993-06-24 |
2006-04-01 |
Advec Inc. |
Vectores de adenovirus para terapia genica.
|
|
SK283703B6
(sk)
|
1993-10-25 |
2003-12-02 |
Canji, Inc. |
Rekombinantný adenovírusový vektor a jeho použitie
|
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US6682741B1
(en)
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
CA2424158A1
(en)
|
2000-09-29 |
2002-04-11 |
The Scripps Research Institute |
Labeled peptides, and processes and intermediates useful for their preparation
|
|
AU2002253283A1
(en)
*
|
2001-03-19 |
2002-10-03 |
Isis Innovation Limited |
Mutated mhc molecules for use in immune suppression
|
|
DK2322631T3
(en)
|
2001-04-19 |
2015-01-12 |
Scripps Research Inst |
Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2005081716A2
(en)
|
2003-11-24 |
2005-09-09 |
The Johns Hopkins University |
DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
|
|
GB0329146D0
(en)
*
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
CA2611946C
(en)
|
2005-06-20 |
2013-04-16 |
Cadila Healthcare Limited |
Expression vector and methods of producing high levels of proteins
|
|
US7521195B1
(en)
|
2005-07-21 |
2009-04-21 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
EP2863222A1
(en)
|
2006-03-06 |
2015-04-22 |
Amunix Operating Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
EP2328920A2
(en)
*
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
EP2365979A2
(en)
*
|
2008-10-22 |
2011-09-21 |
Biogen Idec MA Inc. |
Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
|
|
JP5851243B2
(ja)
|
2008-11-30 |
2016-02-03 |
イミューサンティー インコーポレーテッドＩｍｍｕｓａｎＴ，Ｉｎｃ． |
セリアック病の処置のための組成物および方法
|
|
SI2393828T1
(sl)
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120141537A1
(en)
|
2010-11-18 |
2012-06-07 |
Pease Larry R |
Enhancing t cell activation using altered mhc-peptide ligands
|
|
JP6093712B2
(ja)
*
|
2010-12-22 |
2017-03-08 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン２のスーパーアゴニストおよびアンタゴニスト
|
|
US9540438B2
(en)
|
2011-01-14 |
2017-01-10 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
DK2699593T4
(da)
|
2011-04-20 |
2021-02-08 |
Univ Washington Through Its Center For Commercialization |
Beta-2 mikroglobulin-deficiente celler
|
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
DE112011100879A5
(de)
|
2011-08-30 |
2013-11-14 |
Jacobs University Bremen Ggmbh |
Gen codiert für ein MHC-Klasse-I-Molekül, Plasmid, Expressionssystem, Protein, Multimer, Reagenz und Kit zum Analysieren einer T-Zellen-Frequenz
|
|
HK1204261A1
(en)
|
2012-01-13 |
2015-11-13 |
Memorial Sloan Kettering Cancer Center |
Immunogenic wt-1 peptides and methods of use thereof
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
|
WO2014014821A1
(en)
*
|
2012-07-19 |
2014-01-23 |
Redwood Biosciences, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
JP2016500255A
(ja)
|
2012-12-11 |
2016-01-12 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
ハイスループットなレセプター：リガンド同定の方法
|
|
US20170176435A1
(en)
|
2014-01-21 |
2017-06-22 |
Albert Einstein College Of Medicine, Inc. |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
US11602525B2
(en)
|
2014-04-25 |
2023-03-14 |
Rinat Neuroscience Corp. |
Antibody-drug conjugates with high drug loading
|
|
AU2015271100B2
(en)
|
2014-06-06 |
2020-07-30 |
Redwood Bioscience, Inc. |
Anti-HER2 antibody-maytansine conjugates and methods of use thereof
|
|
JP6652932B2
(ja)
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
ｓｙｎＴａｃポリペプチド及びその使用
|
|
CA2980292A1
(en)
|
2015-03-23 |
2016-09-29 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
EP3590961A1
(en)
|
2015-03-25 |
2020-01-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
|
PH12017502013B1
(en)
|
2015-05-07 |
2022-07-22 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
EP3365678A1
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics GmbH |
Methods for culturing cells and kits and apparatus for same
|
|
US20190062400A1
(en)
|
2016-03-02 |
2019-02-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20180132070A
(ko)
*
|
2016-03-03 |
2018-12-11 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
CN109310739A
(zh)
|
2016-03-31 |
2019-02-05 |
内恩疗法公司 |
新抗原及其使用方法
|
|
CN109071623B
(zh)
*
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
JP7071288B2
(ja)
*
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
DE102016222109A1
(de)
|
2016-11-10 |
2018-05-17 |
Robert Bosch Gmbh |
Brennstoffzellensystem
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
BR112020004535A2
(pt)
|
2017-09-07 |
2020-09-08 |
Cue Biopharma, Inc. |
peptídeos moduladores de células t multiméricos e métodos de uso destes
|
|
CA3074839A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
|
AU2018328283A1
(en)
|
2017-09-07 |
2020-02-20 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
SG11202009761YA
(en)
|
2018-04-02 |
2020-10-29 |
Pact Pharma Inc |
Peptide-mhc compacts
|
|
WO2020132368A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
TW202039541A
(zh)
|
2018-12-19 |
2020-11-01 |
美商庫爾生物製藥有限公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2020132365A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132138A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132366A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
US20200291355A1
(en)
|
2019-02-20 |
2020-09-17 |
Rubius Therapeutics, Inc. |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
EP3935080A4
(en)
|
2019-03-06 |
2023-04-05 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2020243315A1
(en)
|
2019-05-29 |
2020-12-03 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3986448A4
(en)
|
2019-06-19 |
2023-07-12 |
Cue Biopharma, Inc. |
MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2021055594A1
(en)
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
WO2021067404A2
(en)
|
2019-09-30 |
2021-04-08 |
Adimab, Llc |
Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
|
|
WO2021081239A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
CN114423497A
(zh)
|
2019-10-23 |
2022-04-29 |
库尔生物制药有限公司 |
修饰的细胞毒性t细胞及其使用方法
|
|
WO2021195108A1
(en)
|
2020-03-24 |
2021-09-30 |
Cue Biopharma, Inc. |
T cell modulatory polypeptides and methods of use thereof
|
|
US20230117521A1
(en)
|
2020-03-25 |
2023-04-20 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2021242935A1
(en)
|
2020-05-26 |
2021-12-02 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
IL299834A
(en)
|
2020-07-14 |
2023-03-01 |
Cue Biopharma Inc |
with binding sites and methods for using them T - cellular modulatory polypeptides
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
WO2022056015A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2022099157A1
(en)
|
2020-11-06 |
2022-05-12 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
CA3174142A1
(en)
|
2020-11-06 |
2022-05-12 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
WO2022119958A1
(en)
|
2020-12-02 |
2022-06-09 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP4308143A4
(en)
|
2021-03-19 |
2025-06-04 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
CA3209361A1
(en)
|
2021-03-19 |
2022-09-22 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides and methods of use thereof
|
|
EP4326754A4
(en)
|
2021-04-21 |
2025-02-19 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
CN117561280A
(zh)
|
2021-04-21 |
2024-02-13 |
库尔生物制药有限公司 |
携带TGF-β的抗原呈递多肽复合物及其使用方法
|
|
EP4326337A4
(en)
|
2021-04-21 |
2025-02-19 |
Cue Biopharma, Inc. |
MHC CLASS II T-CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
EP4426721A4
(en)
|
2021-11-04 |
2025-10-08 |
Cue Biopharma Inc |
MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
|